> In future studies, Siegwart and his team are hoping to find more ways to use this new CRISPR delivery technology, including in conjunction with existing therapies. “This study…demonstrated the ability to combine multiple therapeutic agents in one nanoparticle. Therefore, we would like to use this strategy for other tumors that have similar measures to their matrix barriers and try other diseases that also have physical barriers, like fibrosis models,” Siegwart said.

Interesting. Excited to see how this plays out.

!RemindMe 10 years.